HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[A Case Report of Sigmoid Colon Cancer with a Synchronous Large Liver Metastasis Curatively Resected Following Multidisciplinary Therapy].

Abstract
A 50's woman referred to our hospital with high serum CEA level was found to have RAS-wild sigmoid colon cancer with a 15 cm size unresectable synchronous liver metastasis(LM)in the right lobe during the endoscopic, radiological, and immunohistological examinations. CapeOX was introduced, but the LM lesion enlarged to 18 cm after 2 courses. Therefore, the regimen was switched to FOLFIRI plus panitumumab. Six courses ofchemotherapy resulted in the reduction ofthe LM lesion to 11 cm, and the Response Evaluation Criteria in Solid Tumors revealed PR with no severe adverse effects, and curative surgical resection was planned. The patient underwent laparoscopic sigmoidectomy resection, followed by percutaneous transhepatic portal embolization(PTPE)ofthe right branch ofthe portal vein to secure the volume ofthe future remnant liver. Right lobectomy and partial resection ofsegment 4 ofthe liver and cholecystectomy was then performed. Currently, 28 months postoperatively, the patient continues to do well with no signs ofrecurrence. This case demonstrates that the sequential combination ofsystemic therapy with FOLFIRI plus panitumumab and PTPE enabled the curative surgical management ofthe sigmoid colon cancer with a large synchronous LM.
AuthorsYozo Suzuki, Manabu Mikamori, Takuro Saito, Kenta Furukawa, Masahisa Ohtsuka, Kentaro Kishi, Masahiro Tanemura, Hiroki Akamatsu
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 45 Issue 13 Pg. 1979-1981 (Dec 2018) ISSN: 0385-0684 [Print] Japan
PMID30692417 (Publication Type: Case Reports, Journal Article)
Topics
  • Antineoplastic Combined Chemotherapy Protocols
  • Embolization, Therapeutic
  • Female
  • Hepatectomy
  • Humans
  • Liver Neoplasms (secondary, therapy)
  • Middle Aged
  • Portal Vein
  • Sigmoid Neoplasms (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: